NDAINTRAVENOUSPOWDER
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
DAPTOMYCIN (daptomycin) by Hikma is 12. Approved for bacteremia, soft tissue infections, staphylococcal skin infections and 5 more indications. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daptomycin is a lipopeptide antibiotic administered intravenously that treats serious gram-positive bacterial infections including bacteremia, endocarditis, and skin infections. It works by disrupting bacterial cell membrane integrity, with efficacy correlating to AUC/MIC ratio in animal models.
Peak12.3 years to LOE
Peak-stage IV antibiotic with established market presence; brand teams focus on market maintenance and indication expansion rather than primary launch activities.
Mechanism of Action
12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ]. 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for certain…
Worked on DAPTOMYCIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.